Home › Alpha-1 Antitrypsin Deficiency › New York
Alpha-1 Antitrypsin Deficiency clinical trials in New York
4 studies for Alpha-1 Antitrypsin Deficiency are looking for participants at sites in New York.
Cities in New York
Gene Therapy for Alpha 1- Antitrypsin Deficiency
- WCMC Department of Genetic Medicine, New York
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT06996756Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated May 13, 2026 · NCT05677971Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- NYU Langone Medical Center, New York
- Columbia University Irving Medical Center, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Mar 5, 2026 · NCT06165341PiMZ Longitudinal Cohort (PiMZ Logic)
- Columbia University Irving Medical Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT06505603From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.